Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Real Hope For Lupus As AZ's Anifrolumab Impresses In Phase II

This article was originally published in Scrip

Executive Summary

A Phase II trial of AstraZeneca's investigational monoclonal antibody, anifrolumab, in patients with moderate-to-severe systemic lupus erythematosus (SLE) met its primary and secondary endpoints. The data were presented at the American College of Rheumatology 2015 Scientific Meeting in San Francisco this week.

You may also be interested in...



New Life For AstraZeneca’s SLE Treatment As Second Study Succeeds

The second Phase III TULIP trial for AstraZeneca’s anifrolumab has succeeded where the first failed by hitting a new primary endpoint in systemic lupus erythematosus.

TULIP Fever: AstraZeneca Catches Cold With Disappointing Lupus Data

Another one of AstraZeneca’s more left-field product candidates, its investigational lupus therapy anifrolumab, has disappointed at Phase III.

Deal Watch: Array Partners With Ono On Cancer Drugs In Japan, South Korea

French biotechs Servier and ILTOO sign an option agreement for the latter's IL-2 inhibitor for lupus, while Korean biotechs LegoChem and Bridge will team up in idiopathic pulmonary fibrosis.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC030281

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel